High-sensitivity cardiac troponins (Hs-cTns) are reliable indicators of myocardial injury, but their relationship with cardiovascular outcomes remains less understood. This study explored the association between adverse cardiac events and Hs-cTnT levels exceeding 14ng/L in patients with stable CAD. Thirteen pertinent studies were identified using specific keywords from a pool of 208 articles retrieved from PubMed, Scopus, and Google Scholar, spanning 2013 to 2023. The primary outcomes included all-cause mortality (ACM), myocardial infarction (MI), cardiovascular death (CVD), rehospitalization due to decompensated heart failure (RDHF), need for revascularization, and stroke. Comprehensive meta-analysis (CMA) was employed to analyze the data for odds ratios (OR) and 95% confidence intervals (CI). Heterogeneity was assessed using I2 statistics, and both qualitative assessment (Newcastle-Ottawa Scale) and quantitative analysis (Egger's and Beggs test, funnel plots) were conducted. The analysis included 29,115 participants (74.72% male) with a mean age of 68.34 years. It revealed a significantly elevated risk of ACM among stable CAD patients with Hs-cTnT levels > 14ng/L compared to those with levels <14ng/L (11.2% vs. 3.3%; OR 5.46; 95% CI: [1.53, 19.54]; p = 0.009). Similarly, higher risks were observed for MI (10.9% vs 3.6%; OR 3.12;, 95% CI: [0.98, 9.95], p = 0.053, CVD (8.1% vs. 2.1%; OR 3.37; 95% CI: [1.74, 6.50]; p < 0.0001), and RDHF (6.62% vs. 0.92%; OR 9.46; 95% CI: [4.65, 19.24]; p < 0.0001). Notably, major adverse cardiovascular events (MACE) exhibited a stronger association with Hs-cTnT levels (18.2% vs 7.81%; OR of 1.89; 95% CI: [0.80, 4.43]; I2 = 97%; p = 0.14) compared to Hs-cTnI levels (20.1% vs 21.1%; OR 1.30; 95% CI: [1.03, 1.64]; I2 = 14ng/L) are significantly associated with increased risks of RDHF and ACM in patients with stable CAD. Further large-scale prospective studies are warranted to refine risk assessment strategies and mitigate cardiovascular mortality in this population.

The mortality trends associated with the mpox virus (MPXV) are not well defined. This study aims to systematically assess the mortality rate of mpox and its stratification across different geographical locations. Comprehensive review of articles from the PubMed, Embase, Scopus, and Web of Science databases up to June 2025, focusing on studies reporting mortality rates among patients diagnosed with mpox. A random-effects proportional meta-analysis assessed global and regional mpox mortality rates and their geographical variations. Sensitivity analysis using one-study removal method and meta-regression analyses were conducted. Out of 4,098 records, 30 articles met the selection criteria, comprising a total of 47,311 patients diagnosed with mpox. The pooled global mpox mortality rate was 3.1% (95% CI: 1.6%-5.9%). Mortality was significantly higher before 2016 at 11.4% (95% CI: 5.8%-21.1%), compared to 2.4% (95% CI: 1.2%-4.7%) during 2016-2025, and declined further in the post-COVID era to 1.5% (95% CI: 0.7%-3.4%). Mortality was markedly elevated among individuals with HIV co-infection (83.8%; 95% CI: 74.0%-90.5%). Regionally, mortality was highest in Africa (6.3%) and lowest in Europe (0.1%). Among studies conducted in endemic regions, a notable temporal decline was also observed, with mortality decreasing from 11.4% before 2016 to 4.1% during 2016-2025. Meta-regression identified year of publication as a significant predictor of mortality (p = 0.028), indicating improved outcomes over time. Global mpox mortality has declined over time, particularly in endemic regions and the post-COVID era. However, individuals with HIV remain at exceptionally high risk, underscoring the need for targeted interventions.